Skip to Content

Posts tagged with "Drug Development"

  • Drug Development

    Is The FDA the Problem?

    A reader sends along this account of some speakers at last year’s investment symposium from Agora Financial. One of the speakers was Juan Enriquez, and I thought that readers here might be interested in his perspective. First, the facts. According to Enriquez: Today, it costs 100,000 times less than it once did to create a… Read More
  • Drug Development

    A Regeneron Profile

    In the spirit of this article about Regeneron, here’s a profile in Forbes of the company’s George Yancopoulos and Leonard Schleifer. There are several interesting things in there, such as these lessons from Roy Vagelos (when he became Regeneron’s chairman after retiring from Merck): Lesson one: Stop betting on drugs when you won… Read More
  • Drug Development

    Druggability: A Philosophical Investigation

    I had a very interesting email the other day, and my reply to it started getting so long that I thought I’d just turn it into a blog post. Here’s the question: How long can we expect to keep finding new drugs? By way of analogy, consider software development. In general, it’s pretty hard to… Read More
  • Drug Development

    How Much to Develop a Drug? An Update.

    I’ve referenced this Matthew Herper piece on the cost of drug development several times over the last few years. It’s the one where he totaled up pharma company R&D expenditures (from their own financial statements) and then just divided that by the number of drugs produced. Crude, but effective – and what it said was… Read More
  • Drug Development

    An Interview With A GSK Shanghai Scientist

    Here’s an interview with Liu Xeubin, formerly of GlaxoSmithKline in China. That prospect should perk up the ears of anyone who’s been following the company’s various problems and scandals in that country. Liu Xuebin recalls working 12-hour shifts and most weekends for months, under pressure to announce research results that would… Read More
  • Academia (vs. Industry)

    The NIH’s Drug Repurposing Program Gets Going

    Here’s an update on the NIH’s NCATS program to repurpose failed clinical candidates from the drug industry. I wrote about this effort here last year, and expressed some skepticism. It’s not that I think that trying drugs (or near-drugs) for other purposes is a bad idea prima facie, because it isn’t. I just wonder about… Read More
  • Business and Markets

    Salary Freeze at Lilly

    We now return to our regularly schedule program around here – or at least, Eli Lilly is now returning to theirs. The company announced that they’re freezing salaries for most of the work force, in an attempt to save hundreds of millions of dollars in advance of their big patent expirations. Some bonuses will be… Read More
  • Business and Markets

    Good Advice: Get Lost!

    I thought everyone could use something inspirational after the sorts of stories that have been in the news the last few days. Here’s a piece at FierceBiotech on Regeneron, a company that’s actually doing very well and expanding. And how have they done it? Regeneron CEO Dr. Leonard “Len” Schleifer, who founded the company in… Read More
  • Business and Markets

    The GSK Jackpot

    Well, this got my attention: according to the Sunday Times, GlaxoSmithKline is preparing to hand out hefty bonus payments to scientists if they have a compound approved for sale. Hefty, in this context, means up to several million dollars. The earlier (and much smaller) payouts for milestones along the way will disappear, apparently, to be… Read More
  • Clinical Trials

    The Last PPAR Compound?

    Roche has announced that they’re halting trials of aleglitazar, a long-running investigational drug in their diabetes portfolio. I’m noting this because I think that this might be the absolute last of the PPAR ligands to fail in the clinic. And boy howdy, has it been a long list. Merck, Lilly, Kyorin, Bristol-Myers Squibb, Novo Nordisk… Read More